Radar on Drug Benefits

FDA OK’s IL-17As for nr-axSpA, But Few See Changes Ahead With Chart: Current Market Access to Ankylosing Spondylitis Medications

The FDA’s approvals of two interleukin-17A (IL-17A) antagonists to treat active non-radiographic axial spondyloarthritis (nr-axSpA) give providers new options for patients who are intolerant of non-steroidal anti-...
0 Comments

News Briefs

✦ Kaiser Permanente is joining Civica Rx – the not-for-profit generic drug company run by health systems and hospitals — as a governing member with a seat on the board of directors. Civica, which was founded i...
0 Comments

Blues Plans Sue CVS, Alleging It Overcharged for Generic Drugs

In a move that one attorney says may have a domino effect, Blue Cross Blue Shield plans recently filed suit against CVS Health Corp., claiming that the firm fraudulently overcharged them for generic drugs by “subm...
0 Comments

MedImpact Hopes to Accelerate Adoption of Pharmacogenomics

With precision medicine an increasingly hot topic in health care, MedImpact is betting that a newly launched program — which reviews every drug prescribed to patients against their genetic profile — will simulta...
0 Comments

Antibody Drug Conjugates Are Worth Watching, OptumRx Says

In its newest Drug Pipeline Insights Report, OptumRx highlighted recently approved or soon-to-be-approved drugs that might significantly impact payers and patients. In its latest quarterly report, though, the United...
0 Comments

Studies Paint Nuanced Picture of Insulin Out-of-Pocket Costs

Medicare enrollees this fall will be able to sign up for prescription plans that cap copayments for insulin at $35 a month. A recent Kaiser Family Foundation analysis shows that average annual out-of-pocket spending...
0 Comments

Pricey Cures Pose Reinsurance, Cost-Sharing Challenges

Genomic, curative drugs for chronic and terminal diseases are perhaps the most exciting new treatments in medicine. But even though these highly tailored therapies come to market with the potential to save costs for...
0 Comments

News Briefs

✦ This month, the federal government’s supply of remdesivir will run out, CNN reported. The antiviral drug is a palliative treatment for COVID-19 with documented clinical effectiveness, and is so far the only tr...
0 Comments

With One Drug-Supply Issue in Check, Another May Be Looming

While the COVID-19 pandemic led to worrying spikes in demand for certain drugs back in March and April — spurring PBMs to swiftly establish dispensing limits — that particular storm appears to have passed. Howev...
0 Comments

Scarcity, Geography Will Shape COVID-19 Vaccine Rollout

The rollout of a vaccine for SARS-CoV-2, the virus that causes COVID-19, is an unprecedented logistical challenge. So will be deciding who gets it: experts say that the initial vaccine supply will not be large enoug...
0 Comments